JAK inhibition decreases the autoimmune burden in Down syndrome is a research paper published in medRxiv (2024). On theSindex it has a DataRank of 0.208. It has been cited 3 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →National Institutes of Health
Grant: 2T32AR007411-31A1
Training in Immunodermatology
National Institutes of Health
Grant: 1UM1TR004399-01A1
Colorado Clinical and Translational Sciences Institute (CCTSI)
National Institutes of Health
Grant: 5T32CA190216-03
Training Program in Cancer Biology
National Institutes of Health
Grant: 1R61AR077495-01
JAK Inhibition in Down Syndrome
National Institutes of Health
Grant: 3P30CA046934-20S2
Cancer Center Support Grant
National Institutes of Health
Grant: 1R01AI150305-01
Understanding Down Syndrome as an Interferonopathy
NIAID NIH HHS
Grant: R01 AI150305
NCI NIH HHS
Grant: P30 CA046934
NIAMS NIH HHS
Grant: R61 AR077495
NCATS NIH HHS
Grant: UM1 TR004399
NIAMS NIH HHS
Grant: T32 AR007411
NCI NIH HHS
Grant: T32 CA190216
Fields of Study
Keywords
Sustainable Development Goals